Objective Prior studies report statins may reduce the risk of advanced prostate cancer. This study investigates the association between statin use and the likelihood of having a PSA or DRE test, blood PSA levels, prostate volume, and the severity of lower urinary tract symptoms. We also describe the association between statin use and prostate cancer and high-grade prostatic intraepithelial neoplasia (PIN) before and after controlling for prostate cancer screening indices associated with statin use. Methods The Nashville Men's Health Study used a multicenter, rapid recruitment protocol to collect clinical, biologic, behavioral, and body measurement data from 2,148 men 40 years or older scheduled for diagnostic prostate biopsy. Medication use and other data were ascertained by research survey, clinical interview, and chart review. Results Approximately 37% of participants were taking a statin. Statin use was significantly associated with a 12% lower PSA levels and 8% smaller prostate volume after controlling for age, race, BMI, WHR, aspirin use, and other comorbidity. Simvastatin was more strongly associated with prostate volume, while atorvastatin was associated with PSA. Statin use was marginally associated with increasing PSA test frequency among men with undiagnosed cancer. Statin use was not associated with the frequency or results of digital rectal exams, lower urinary tract symptom severity, high-grade (Gleason [ 6) prostate cancer (OR = 0.95 (0.73, 1.24)), low-grade (Gleason = 6) prostate cancer (OR = 1.11 (0.86, 1.42)) or PIN (OR = 0.82, (0.57, 1.17)). Additional control for the number of prior PSA tests, PSA levels, and prostate volume did not alter these results. Conclusion These results suggest selective referral for biopsy associated with statin use is an essential element to address in further understanding the potential for statins to prevent prostate cancer.
Introduction
Prior reports that men with lower cholesterol levels have a lower risk of prostate cancer have suggested that small molecule inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMGCoA) reductase, known as statins, may reduce prostate cancer risk [1, 2] . Statins inhibit prenylation and the activity of several key cellular regulatory elements, blocking cholesterol synthesis [3] , but also affect regulatory mechanisms of apoptosis, cell proliferation, cell migration, and the inflammatory response [4] . Several recent studies, including prospective analyses from the Health Professionals Follow-up Study and the Cancer Prevention Study II, reported that extended statin use lowered the risk of advanced, aggressive, or clinically relevant forms of prostate cancer [5] [6] [7] [8] [9] [10] . The California Men's Health Study reported a non-significant protective association between statin use and advanced prostate cancer [11] , while analysis of the Kaiser Permanente Medical Care Program in northern California found statin use was associated with a decrease in advanced disease but also an increase in localized prostate cancer [12] . The European Randomized Study of Prostate Cancer Screening, with few advanced cases, found statin use reduced the risk of earlystage prostate cancer [13] . In contrast, an analysis of 236 prostatectomy patients within the Veteran's Administration found simvastatin use was associated with detection of high-grade prostate cancer at biopsy [14] , while a population-based case-control analysis found statin use increased prostate cancer risk among obese men [15] .
Increasing utilization of the prostate-specific antigen test (PSA) within a population leads to a dramatic increase in the detection of localized prostate cancer. This has raised the concern that previously observed stage-specific associations between statins and prostate cancer may derive from differential prostate cancer detection between statin users and non-users. Indeed, several studies now report statin use is associated with an increase in PSA testing [7, 9] , lower PSA levels [9, 16, 17] , and fewer prostate biopsies [10] . With increasing PSA testing, there is the potential for increasing the detection of localized disease at the expense of advanced cancer, lending the appearance of a protective association between statin use and advanced prostate cancer. Furthermore, lower PSA levels may prevent referral for a diagnostic prostate biopsy, also lending to the appearance of a reduced cancer risk. Beyond the impact on clinical referral for biopsy, any relationship between statin use and prostate size may also affect the stage/grade at diagnosis, as analyses from the Prostate Cancer Prevention Trial suggest that a smaller prostate size improves the efficiency of prostate biopsy to detect small, high-grade, prostate cancer foci [18] . Although a recent randomized trial found atorvastatin administration for 6 months was insufficient to reduce prostate size among men with normal to borderline LDL levels [19] , the possible effects of statin on prostate size among men at risk for prostate cancer is not understood.
Before recommending statins for the prevention of prostate cancer, the relationship between statin use and the range of individual and clinical factors involved in detecting and diagnosing prostate cancer needs to be determined. Here, we investigate the association between cholesterol-lowering medications, including statins, and PSA testing frequency, blood PSA levels, DRE results, prostate volume, LUTS severity, and the risk of PIN, lowgrade prostate cancer, and high-grade prostate cancer, while controlling for body size [15, 20] , aspirin use [21] , and comorbidity such as diabetes and cardiovascular disease (CVD) [22] . Our results may identify prostate cancer screening and detection factors that most influence an association between statin use and prostate cancer risk, and ultimately may serve to better target statin use to those men most likely to benefit.
Materials and methods

Study population
All participants provided written informed consent with guarantees of confidentiality prior to data collection in accordance with the Vanderbilt University IRB. Men scheduled for a diagnostic prostate biopsy between 2002 and 2010 at a Vanderbilt University Medical Center (Nashville, TN), the Tennessee Valley Veteran's Administration Hospital (Nashville, TN), or Urology Associates, a private urology clinic in Nashville, were approached for recruitment. Eligible participants were 40 years of age or older and had no prior prostate cancer diagnosis. Approximately 95% of eligible men approached for recruitment agree to participate, and the study population included 2,509 eligible consenting subjects.
Data collection
Measures of body size and weight were collected by a trained research staff member at the time of recruitment using standardized protocols. Participants wore a hospital gown or other light clothing, and did not wear shoes. Chart review included age, race, PSA history, DRE history, and prostate needle-biopsy result (cancer, PIN, negative, or a suspicious, atypical, or other diagnosis). Gleason scores at biopsy were also ascertained for subjects diagnosed with cancer following pathology review of the biopsy specimen, and high-grade cancer was defined by a biopsy Gleason sum score of 7 or higher. A suspicious DRE included a report of nodularity, firmness, induration, or asymmetry at the most recent DRE relative to the biopsy. Prostate volume (mls) was measured by transrectal ultrasound (TRUS) during the prostate biopsy procedure. PSA density was calculated (PSA (ng/ml)/volume (mls)) as an index of PSA produced per unit of prostate. Family history of prostate cancer was ascertained from the surgical chart and by a structured research questionnaire administered to each participant at recruitment. Subjects with a family history recorded on the medical chart or reporting a family history by questionnaire were considered positive for a family history. Severity of lower urinary tract symptoms (LUTS) was initiated in 2008 using the International Prostate Symptom Score, and 379 participants provided LUTS severity scores.
As a part of the pre-biopsy clinic visit, all subjects record all current medications on a medication record form. Subjects are instructed to make a list of all current medications at home or to bring their medications to this clinic visit. Medications reported on the medication record form were entered into the subject's computerized medical record. However, duration of drug use was not recorded. Prior to biopsy, the surgeon reviews responses with the subject to confirm current medication status for the listed drugs. Additionally, the surgeon makes specific queries for drugs that might affect bleeding, blood pressure, or clotting during the biopsy procedure. In addition to the statins, prescription and non-prescription medications to treat CVD, diabetes, hyperlipidemia, and benign prostatic hyperplasia were ascertained, as well as regular use of aspirin and other prescription and non-prescription nonsteroidal anti-inflammatory drugs (NSAIDs). Drugs formulated as a combination of two or more active drugs were re-classified by the component drugs.
Data analysis
From the 2,509 consenting subjects, we excluded men with atypia or uncertain pathology findings (n = 44), or taking exogenous testosterone (n = 24) or a steroid reductase inhibitor (finasteride, dustasteride, n = 156). We also excluded 11 men with a BMI less than 18.5 to reduce any influence of severe morbidity, and 126 participants were excluded because prostate volume or PSA data were missing from the medical record. The analytic study population involved 2,148 participants, including 844 patients with cancer, 185 patients with PIN, and 1,119 controls without cancer or PIN at biopsy.
The association between statin use and the number of prior PSA tests or DREs was first evaluated using a Mantel-Haenszel chi-square test. Ordinal logistic regression was also used to calculate odds ratios and 95% confidence intervals summarizing the association between statin use and an increasing number of prior screening tests while adjusting for age (continuous), race (black, white, and other), family history (Y/N), prostate volume (continuous), BMI (categorized as 18.5 to \25, 25 to \30, 30 to \35, 35 or more) aspirin use (Y/N), treatment for BPH (Y/N), treatment for diabetes (Y/N), treatment for CVD (Y/N), waist-to-hip ratio (WHR: categorized at quartiles), and height (categorized at quartiles). A similar approach using standard multivariable logistic regression was used to determine the association between statin use and DRE frequency and results.
Mean PSA levels, PSA density, and prostate volume were compared between statin users vs. statin non-users within a multivariable linear model. The distributions of PSA level and prostate volume data were natural log transformed prior to analysis. We compared PSA and volume scores between statin users and non-users while adjusting for age, race, family history, number of prior PSA tests, BMI, WHR, height, treatment for BPH, diabetes, or CVD, and the diagnosis of PIN, low-grade cancer, or highgrade cancer following biopsy. Models may also include PSA levels or prostate volume, as indicated within the text. PSA and prostate volume scores were back-transformed, and geometric mean values and percent differences are reported. Separate analyses were developed to investigate the consistency of associations between statin use and PSA or prostate volume by diagnostic category. Tests for interaction were determined by a cross-product term between statin use and diagnosis in the presence of each main-effect and other covariates.
Multivariable logistic regression was used to investigate the association between statin use and the risk of highgrade prostate cancer, low-grade prostate cancer, or PIN. Participants without cancer or PIN at biopsy served as controls, allowing equal data collection and recruitment protocols across case and control participants while reducing the prevalence of latent disease in the control series as much as possible. The impact of prostate screening factors on these associations was evaluated by re-running the analyses after including covariates for the number of prior PSA tests, prostate volume, PSA levels and other parameters.
Results
Study population
Participants included men between 40 and 94 years of age, with an average age of 65.1 years (Table 1) . Approximately 34% had a BMI of 30 or more, 11% were of nonwhite race/ethnicity, and 52% were without cancer or PIN at biopsy. The majority of participants were taking medications for the treatment of CVD, including amlodipine (n = 201), atenolol (n = 137), enalapril (n = 38), hydrochlorothiazide (n = 231), lisinopril (n = 365), or other medications. Approximately 13% were being treated for diabetes, including thiazolidenediones (n = 71), metformin (n = 165), insulin (n = 52), sulfonoureas (n = 124), or other medications. Almost 20% of participants were being treated for BPH symptoms with alfuzosin (n = 36), tamsulosin (n = 236), or similar medications. (n = 77), rosuvastatin (n = 66), pravastatin (n = 36), and fluvastatin (n = 15). There were 74 participants taking a non-statin lipid medication, including ezetimibe (n = 25), fenofibrate (n = 21), gemfibrozil (n = 8), cholestyramine (n = 5), and niacin (n = 24) (not mutually exclusive). Statin users tended to be older than non-statin users, and also had a higher BMI and WHR, were more likely to take aspirin regularly, and were more likely to be treated for diabetes or CVD (Table 1) .
Statins and frequency of PSA or DRE Table 3 ). Cholesterol-lowering medication use was not significantly associated with PSA density. A similar pattern was seen among statin users and among men taking a non-statin medication, although the number of non-statin users was limited and associations were not statistically significant. We further explored the effects of each statin on PSA and prostate volume. Simvastatin was significantly associated with a smaller prostate volume, but was not significantly associated with PSA levels. Atorvastatin, in contrast, was significantly associated with lower PSA levels. Rosuvastatin was marginally associated with prostate volume and PSA levels, while fluvastatin, lovastatin, and pravastatin uses were rare and not associated with prostate volume or PSA. Additional exclusion of participants using other types of lipid-lowering medications did not substantially affect the results.).
Statins in association with PSA and prostate volume; by diagnostic group Age-adjusted mean PSA levels were highest among highgrade cancer cases (8.5 ng/ml), but similar among lowgrade cancer cases (5.5 ng/ml), PIN cases (5.5 ng/ml), and controls (4.8 ng/ml). High-grade cancer cases also had the smallest prostate size (age-adjusted mean = 33.5 mls), followed by low-grade cases (39.0 mls), PIN cases (44.3 mls), and controls (46.6 mls). Statin use was associated with lower PSA levels and a smaller prostate volume within participants found to have cancer, PIN, or a negative biopsy (Table 4) . Tests for interaction between statin use and diagnostic group were not significant. Differences in PSA levels were larger with atorvastatin use, and atorvastatin use was significantly associated with lower PSA levels among high-grade cancer cases and within control participants with a negative biopsy. Simvastatin use was associated with prostate volume across diagnostic groups, with statistically significant differences among cancer cases.
Statins and prostate cancer
Statin use was similar between cases and controls (Gleason 8-10 cancer (35.0%); Gleason 7 cancer (38.0%); Gleason 6 
Discussion
Statin use was significantly associated with lower PSA levels and a smaller prostate volume, marginally associated with increased PSA testing frequency, but not associated with DRE or LUTS severity. Statin-specific analyses found atorvastatin use was significantly associated with PSA 
PSA
We confirmed and further generalize the results from several recent studies reporting lower PSA levels among statin users in the U.S. general population [16] , a Veteran's Administration hospital [17] , or in study populations of men with or without prostate cancer [10, 13, 14, 23, 24] . Thus, while statins seem to affect blood PSA levels to some extent, the mechanisms mediating such an affect remain unclear. Statin use may limit steroid hormone synthesis by limiting the production of lipid precursors; however, statin use has not been associated consistently with androgen levels [25] . Nevertheless, prior studies suggest that the effect of statins may be mediated through lower blood lipid levels [2, 17] , and our observation that statin and non-statin cholesterol medications had similar associations with PSA levels may support a mediating role for blood lipids.
Statins also may alter the activity of Ras and Ras-like proteins, CEBPE/F, p21, p27, and elements of the MAPK and PI3 K-ATK pathways [26] , further affecting NF-kB activation and the inflammatory response [4] and possibly preventing PSA escape to the vasculature.
Prostate volume
Prostate enlargement is common as men age [27] , and clinical BPH and prostate enlargement have, to varying degrees, been associated with obesity [28] , hypertension [29] , and serum LDL levels [30] . We found that statin use was associated with an 8% smaller prostate volume, independent of diagnostic group, BMI, or aspirin use. Higher cholesterol levels have been associated with prostate tissue inflammation [14] , and inflammatory infiltrates within the prostate may generate a tissue microenvironment conducive to prostate enlargement, BPH, or prostate cancer [31] . The cholesterol pre-cursor squalene was also associated with a diagnosis of prostate cancer [32] . Thus, perhaps cholesterol-lowering medications sufficient to control hyperlipidemia are also able to reduce tissue inflammation, avoiding inflammation-induced cell damage and proliferation, and delaying prostate cancer or BPH progression. We considered the possibility that a smaller prostate size improves biopsy efficiency to detect highgrade prostate cancer [18] , but the effects of statins on prostate size were consistent across Gleason grades, and we did not see substantive differences in cancer Gleason scores between statin users and non-users. Our exploration of statin sub-types found the decrease in prostate size associated with simvastatin use, and that controlling for the effects of simvastatin on prostate volume accounted for somewhat lower PSA levels among simvastatin users. In contrast, atorvastatin use was not significantly associated with prostate volume. These statinspecific associations were not hypothesized prior to the study, but if true may be related to differences in drug lipophilicity, binding affinity to targeted proteins, or alternatively there could be underlying differences between atorvastatin and simvastatin users that were not controlled in our analyses. Interestingly, the Finnish section of the ERSPCS found hydrophilic statins similar to atorvastatin were more strongly associated with prostate cancer prevention than other statins, while Moyad and colleages reported that atorvastatin improved biochemical progression-free survival following brachytherapy [33] . Gene expression and protein expression profiles within prostate tissue are needed to characterize the effects of specific statins.
PSA testing frequency
Several studies now report that statin use is associated with having at least one PSA test [7-9, 11, 15] . Differences in health-seeking behaviors between statin users vs. non-users may involve the willingness to attend more frequent healthcare visits and routine blood collection over an extended period of time to monitor blood lipid levels among men treated for dyslipidemia. There was a marginally significant increase in the number of PSA tests among men receiving cholesterol-lower medication, such that the age-adjusted likelihood of having a follow-up PSA test increased about 13% among men taking cholesterollowering medications. This pattern was similar among statin users, although not as strong. Furthermore, these relationships were specific to participants harboring as yet undiagnosed prostate cancer. In our study, statin use was significantly associated with treatment for comorbidities, aspirin use, and obesity, and an association between cholesterol-lowering medication use and PSA testing practices may reflect some fundamental differences in healthcare practice patterns between men receiving routine medical care to monitor lipid profiles. Controlling for factors related to comorbidity status reduced the association with PSA testing somewhat, although not completely. Enhanced PSA testing was somewhat greater among men diagnosed with low-grade disease (not shown) and may suggest a more frequent screening procedure among statin users with marginal PSA levels. A DRE would not be routinely performed during clinical follow-up for dyslipidemia, and we found no association between statin use and DRE frequency or DRE results.
Statins, prostate cancer, and PIN Protective associations between statin use and advanced prostate cancer were reported in the HPFS and the CPS-II [8, 9] . These studies collected PSA test history data from study participants and concluded that differences in the likelihood of a prior PSA test with statin use did not substantially affect their results. The Olmsted County study reported statin use was associated with a decreased risk of prostate cancer and high-grade prostate cancer after controlling for diabetes, CVD, BPH treatment, and NSAID use [10] . Interestingly, the CMHS also found extended statin use was associated with decreased prostate cancer risk, although the majority of men had been screened and most prostate cancer was diagnosed as localized disease [11] . Perhaps the strongest control for preferential prostate cancer detection, however, was within a recent analysis from the Finnish arm of the European Randomized Study of Prostate Cancer Screening [13] . PSA test administration was standardized within the intervention design, and statin use was associated with a lower risk of early-stage or lowgrade prostate cancer and a suggested but non-significant protective association with advanced prostate cancer. In contrast to the above, we found cholesterol-lowering medications were was not significantly associated with prostate cancer or PIN. Our analysis shares components of the CMHS and ERSPCS analyses in that the study population had access to healthcare and prostate cancer screening. We were also able to control for potential sources of detection bias associated with PSA testing frequency, PSA levels, and prostate size, hypothesizing that the any protective association may develop once we controlled for differences in screening and detection. However, adjusting for these factors did not substantially change the associations, or somewhat attenuated the association. It is possible that statins inhibit prostate carcinogenesis during an earlier phase than we were able to observe, and a protective association between simvastatin and PIN may support this possibility. Also, an association may have developed if we had data regarding duration of statin use. It may also be possible that statin users with latent cancer were selectively referred for biopsy, independent of PSA testing frequency, PSA levels, and prostate size. To produce a 'null' association, statin users with latent cancer need to be preferentially biopsied up to a level almost identical to controls without latent cancer (see Results). To the extent that such a selective referral by undiagnosed disease could also be selective for specific statins, this could also contribute to the observed significant increased risk of Gleason 6 prostate cancer associated with atorvastatin. Prostate size differed between diagnostic groups, and prostate enlargement may be a contributing factor toward LUTS severity and thus perhaps biopsy referral. However, consistent with a prior study [19] we did not find an association between statin use and LUTS severity. Prior case-control and cohort analyses have reported a modest increase in risk of prostate cancer associated with statin use [12, 15] . However, a positive association between atorvastatin and Gleason 6 prostate cancer may also be a chance finding, and this is the first investigation of statin use and PIN risk. As such, replication of statin-specific associations is required.
Strengths and limitations
Strengths of this study include ability to ascertain PSA testing history, blood PSA levels, DRE results, LUTS, and prostate volume in a single study population. We also were able to ascertain prostate cancer screening data and the types of statins used through medical chart review, minimizing error, and avoiding potential reporting biases. The usual concerns of response bias derived from missing data on medication reporting forms are minimized because all patients must complete these forms prior to biopsy. All drug intakes were captured prior to biopsy or subject's knowledge of disease status, removing the potential for recall bias. Furthermore, evaluation of subjects seeking a diagnostic biopsy provided a means to control for selective biopsy referral and PSA testing practices previously shown to be associated with statin use and known to determine stage at diagnosis. We were also able to identify PIN cases and subjects without latent cancer or PIN at biopsy, reducing a null bias that can occur when cancer cases or PIN cases are included in the control group. Our investigation of PIN cases also allowed us to consider a precancer phenotype and evaluate an earlier phase of prostate carcinogenesis. Body size was measured by trained staff and standardized protocols. Participants taking finasteride or dutasteride were removed from the analysis, and we controlled for the use aspirin, BMI, WHR, and other treatment for BPH, diabetes, or CVD.
An important limitation of this analysis is that we were unable to capture with confidence data regarding duration or dose of statin use. Prior studies report a weaker association, or no association, between current statin use and prostate cancer [9, 11] , and it is possible that we might have seen a stronger association among those participants with extended statin use. As discussed above, a null-bias or spurious positive association between statin use and prostate cancer could occur if statin users with latent cancer selectively receive biopsy beyond controlling for PSA, prostate volume, PSA testing frequency, aspirin, obesity, and comorbidity.
Conclusions
Statin use was significantly associated with lower PSA levels and a smaller prostate volume, and marginally associated with an increasing frequency of PSA testing among men suspected of harboring latent cancer. Among men referred for prostate biopsy, statin use was not consistently associated with a diagnosis of prostate cancer, although exploratory analyses found simvastatin and atorvastatin were associated with PIN or low-grade cancer, respectively. Selective referral for biopsy associated with Cancer Causes Control (2011) 22:417-426 425 statin use is an essential element to address in future evaluations of statins and prostate cancer prevention.
